×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ACRV – acrivon therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ACRV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/9
07:18 am
acrv
Acrivon Therapeutics (NASDAQ:ACRV) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Acrivon Therapeutics (NASDAQ:ACRV) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
1/8
07:30 am
acrv
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
High
Report
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
1/6
07:30 am
acrv
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
High
Report
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
12/30
04:09 pm
acrv
Acrivon Therapeutics (NASDAQ:ACRV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Acrivon Therapeutics (NASDAQ:ACRV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
12/23
04:09 pm
acrv
Acrivon Therapeutics (NASDAQ:ACRV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Acrivon Therapeutics (NASDAQ:ACRV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
12/17
09:34 am
acrv
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
Medium
Report
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/16
04:03 pm
acrv
Form 4 Acrivon Therapeutics, For: Jan 14 Filed by: Blume-Jensen Peter
Neutral
Report
Form 4 Acrivon Therapeutics, For: Jan 14 Filed by: Blume-Jensen Peter
1/16
04:02 pm
acrv
Form 4 Acrivon Therapeutics, For: Jan 14 Filed by: Levy Adam D.
Low
Report
Form 4 Acrivon Therapeutics, For: Jan 14 Filed by: Levy Adam D.
1/15
04:38 pm
acrv
Form 4 Acrivon Therapeutics, For: Jan 13 Filed by: Devroe Eric
Medium
Report
Form 4 Acrivon Therapeutics, For: Jan 13 Filed by: Devroe Eric
1/8
09:01 am
acrv
Form 8-K Acrivon Therapeutics, For: Jan 08
High
Report
Form 8-K Acrivon Therapeutics, For: Jan 08
1/8
07:30 am
acrv
Form 8-K Acrivon Therapeutics, For: Jan 08
High
Report
Form 8-K Acrivon Therapeutics, For: Jan 08
11/25
04:04 pm
acrv
Form 4 Acrivon Therapeutics, For: Nov 21 Filed by: Blume-Jensen Peter
Low
Report
Form 4 Acrivon Therapeutics, For: Nov 21 Filed by: Blume-Jensen Peter
11/21
05:37 pm
acrv
Form SCHEDULE 13G Acrivon Therapeutics, Filed by: CITADEL ADVISORS LLC
Low
Report
Form SCHEDULE 13G Acrivon Therapeutics, Filed by: CITADEL ADVISORS LLC
11/18
04:34 pm
acrv
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Peterson Katharine
Low
Report
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Peterson Katharine
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: